🇺🇸 FDA
Pipeline program

S-606001 matching placebo, S-606001

2405N1221

Phase 2 small_molecule active

Quick answer

S-606001 matching placebo, S-606001 for Late-onset Pompe disease. is a Phase 2 program (small_molecule) at Shionogi B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Shionogi B.V.
Indication
Late-onset Pompe disease.
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials